Floatz logo

271 assets in Renal Cell Carcinoma

Therapeutic assets addressing Renal Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Sasanlimab
Renal Cell Carcinoma
Stephanie BergP2C (39)
[111in]-fpi-2107
Renal Cell Carcinoma
AstraZenecaP1C (37)
[18f]pt2385
Renal Cell Carcinoma
Orhan Kemal OzP1C (37)
[225ac]-fpi-2068
Renal Cell Carcinoma
AstraZenecaP1C (37)
Acc-1898
Renal Cell Carcinoma
AccSalus Biosciences, Inc.P1C (37)
ai-061
Renal Cell Carcinoma
OncoC4, Inc.P1C (37)
bmc128
Renal Cell Carcinoma
Biomica Ltd.P1C (37)
Bms-986506
Renal Cell Carcinoma
Bristol-Myers SquibbP1C (37)
Bpi-452080
Renal Cell Carcinoma
Betta Pharmaceuticals Co., Ltd.P1C (37)
cht101
Renal Cell Carcinoma
Zhejiang UniversityP1C (37)
Dcc-2812
Renal Cell Carcinoma
Deciphera Pharmaceuticals, LLCP1C (37)
Emunkitug
Renal Cell Carcinoma
HiFiBiO TherapeuticsP1C (37)
Fpi-2053
Renal Cell Carcinoma
AstraZenecaP1C (37)
Gcar1
Renal Cell Carcinoma
Canadian Cancer Trials GroupP1C (37)
hc-7366
Renal Cell Carcinoma
HiberCell, Inc.P1C (37)
hfb200603
Renal Cell Carcinoma
HiFiBiO TherapeuticsP1C (37)
hh160
Renal Cell Carcinoma
Huahui HealthP1C (37)
hlx17
Renal Cell Carcinoma
Shanghai Henlius BiotechP1C (37)
hs-10516
Renal Cell Carcinoma
Jiangsu Hansoh Pharmaceutical Co., Ltd.P1C (37)
Humanized Immunoglobulin G1-Kappa Anti-(Human Cd8) Fused At The C-Terminus Of One Heavy Chain, Via Peptide Linker <Sup>449</Sup> Sggggsggggsggggs<Sup>464</Sup>, To A Variant Of Human Interleukin-2, Glycoform Alfa
Renal Cell Carcinoma
Asher Biotherapeutics, Inc.P1C (37)
Idov-Immune
Renal Cell Carcinoma
ViroMissile, Inc.P1C (37)
Imiquimod
Renal Cell Carcinoma
Toray Industries, IncP1C (37)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Cdh6(Cadherin 6, K-Cadherin (Foetal Kidney), Cadherin 6 Type 2)], Humanized Monoclonal Antibody Conjugated To Deruxtecan, Comprising A Linker And A Camptothecin Derivative
Renal Cell Carcinoma
Daiichi SankyoP1C (37)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Tnfrsf4 (Tumor Necrosis Factor Receptor (Tnfr) Superfamily Member 4, Ox40, Cd134)], Homo Sapiens Monoclonal Antibody
Renal Cell Carcinoma
HiFiBiO TherapeuticsP1C (37)
Itil-306
Renal Cell Carcinoma
Instil BioP1C (37)
Janx008
Renal Cell Carcinoma
Janux TherapeuticsP1C (37)
Modified Vaccinia Virus Ankara Vaccine Expressing P53
Renal Cell Carcinoma
City of Hope Medical CenterP1C (37)
Monoclonal Antibody Trk-950
Renal Cell Carcinoma
Toray Industries, IncP1C (37)
mt-8421
Renal Cell Carcinoma
Molecular Templates, Inc.P1C (37)
Neo-811
Renal Cell Carcinoma
Neomorph, IncP1C (37)
ngm438
Renal Cell Carcinoma
NGM Biopharmaceuticals, IncP1C (37)
ngm831
Renal Cell Carcinoma
NGM Biopharmaceuticals, IncP1C (37)
nm32-2668
Renal Cell Carcinoma
Numab Therapeutics AGP1C (37)
pf-07820435
Renal Cell Carcinoma
PfizerP1C (37)
pf-07826390
Renal Cell Carcinoma
PfizerP1C (37)
pf-07921585
Renal Cell Carcinoma
PfizerP1C (37)
P-Muc1C-Allo1 Car-T Cells
Renal Cell Carcinoma
Poseida Therapeutics, Inc.P1C (37)
QXL138AM
Renal Cell Carcinoma
Nammi Therapeutics IncP1C (37)
RC198
Renal Cell Carcinoma
RemeGen Co., Ltd.P1C (37)
Rimiducid
Renal Cell Carcinoma
Poseida Therapeutics, Inc.P1C (37)
ro7515629
Renal Cell Carcinoma
Hoffmann-La RocheP1C (37)
Tazemetostat
Renal Cell Carcinoma
Oliver JonasP1C (37)
Tocilizumab
Renal Cell Carcinoma
Hoffmann-La RocheP1C (37)
vet3-tgi
Renal Cell Carcinoma
KaliVir ImmunotherapeuticsP1C (37)
Anti-Pd-L1 Monoclonal Antibody Ck-301
Renal Cell Carcinoma
Checkpoint Therapeutics, Inc.P1C (36)
Incb 086550
Renal Cell Carcinoma
Incyte CorporationP2C (36)
Fosifloxuridine Nafalbenamide
Renal Cell Carcinoma
NuCana plcP1/2C (35)
68ga-ny104
Renal Cell Carcinoma
Affiliated Hospital of Jiangnan UniversityEarly P1C (34)
Cytokine Induced Memory-Like Natural Killer Cells
Renal Cell Carcinoma
Dana-Farber Cancer InstituteEarly P1C (34)
Incb099280
Renal Cell Carcinoma
Incyte CorporationP1C (32)
Showing 201 to 250 of 271 assets
PreviousPage 5 of 6Next